Gestodene

Jump to: navigation, search
Gestodene
Gestodene.png
Gestodeno3D.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • X
Routes of
administration
oral administration
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailabilityin vitro 99% using 3H=R5020 / in vivo similar to progesterone
Elimination half-life16 to 18 hrs.
Excretionurinary tract mainly
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H26O2
Molar mass310.430 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Gestodene

Articles

Most recent articles on Gestodene

Most cited articles on Gestodene

Review articles on Gestodene

Articles on Gestodene in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gestodene

Images of Gestodene

Photos of Gestodene

Podcasts & MP3s on Gestodene

Videos on Gestodene

Evidence Based Medicine

Cochrane Collaboration on Gestodene

Bandolier on Gestodene

TRIP on Gestodene

Clinical Trials

Ongoing Trials on Gestodene at Clinical Trials.gov

Trial results on Gestodene

Clinical Trials on Gestodene at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gestodene

NICE Guidance on Gestodene

NHS PRODIGY Guidance

FDA on Gestodene

CDC on Gestodene

Books

Books on Gestodene

News

Gestodene in the news

Be alerted to news on Gestodene

News trends on Gestodene

Commentary

Blogs on Gestodene

Definitions

Definitions of Gestodene

Patient Resources / Community

Patient resources on Gestodene

Discussion groups on Gestodene

Patient Handouts on Gestodene

Directions to Hospitals Treating Gestodene

Risk calculators and risk factors for Gestodene

Healthcare Provider Resources

Symptoms of Gestodene

Causes & Risk Factors for Gestodene

Diagnostic studies for Gestodene

Treatment of Gestodene

Continuing Medical Education (CME)

CME Programs on Gestodene

International

Gestodene en Espanol

Gestodene en Francais

Business

Gestodene in the Marketplace

Patents on Gestodene

Experimental / Informatics

List of terms related to Gestodene

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Gestodene is a progestogen hormonal contraceptive. Products containing gestodene include:

  • Melodene-15, Mirelle, and Minesse which contain 15 mcg of ethinylestradiol and 60 mcg of gestodene;
  • Meliane, Sunya, Femodette, and Millinette 20/75 which contain 20 mcg of ethinylestradiol and 75 mcg of gestodene; and
  • Gynera, Minulet, Femoden, Femodene, Katya and Millinette 30/75 which contain 30 mcg of ethinylestradiol and 75 mcg of gestodene.[1]

Benefits

Gestodene is androgenically neutral, meaning that contraceptive pills containing gestodene do not exhibit the androgenic side effects (e.g. acne, hirsutism, weight gain) often associated with second-generation contraceptive pills, such as those containing levonorgestrel.[2]

The synthetic estrogen dosage in third-generation contraceptive pills (including those containing gestodene) is lower than that in second-generation oral contraceptives, reducing the likelihood of weight gain, breast tenderness and migraine.[3]

Third-generation oral contraceptives are also suitable for use in patients with diabetes or lipid disorders because they have minimal impact on blood glucose levels and the lipid profile.[4]

Adverse effects

Women who take oral contraceptives containing gestodene are 5.6 times as likely to develop thromboembolism than women who do not take any contraceptive pill, and 1.6 times as likely to develop thromboembolism compared to women taking oral contraceptives containing levonorgestrel.[5]

See also

Tigestol Ethynerone
Tigestol
Ethynerone

Footnotes

  1. http://www.bayerscheringpharma.es/ebbsc/cms/es/_galleries/download/s_mujer/prospectos/MelodeneS.pdf
  2. http://dermnetnz.org/treatments/antiandrogens.html
  3. Festin (2006). "Progestogens in combined oral contraceptives for contraception". The WHO Reproductive Health Library.
  4. Cerel-Suhl (1999). "Update on Oral Contraceptive Pills". American Family Physician. 60 (7): 2073–2084.
  5. Lidegaard; et al. (2011). "Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses". BMJ. 343: 1–15. doi:10.1136/bmj.d6423. PMC 3202015. PMID 22027398.
  6. Fried, J.; Bry, T. S.; 1968, Template:US Patent.
  7. DeWinter, M. S.; Siegman, C. M.; Szpilfogel, C. A.; Chem. Ind. (London) 1959, 905.

Linked-in.jpg